The phase III MIRASOL trial randomized MIRV versus the physician’s choice of chemotherapy in platinum-resistant HGSOCs with high FRα tumor expression and reported improved survival in favor of MIRV (median OS of 16.5 versus 12.8 months, HR 0.67, 95% CI, 0.50 to 0.89), p = 0.005 (NCT04209855) [97]. This evidence concerns the gene FOLR1 and neoplasm.